
"Unlocking the Potential: The Promising Bivalent COVID-19 Vaccine as the Ultimate Booster"
A phase 3 study published in The Lancet Respiratory Medicine evaluated the efficacy of a bivalent recombinant protein vaccine for COVID-19. The vaccine, developed by GlaxoSmithKline (GSK) and Sanofi, contains stabilized pre-fusion spike proteins from the ancestral D614 strain and the Beta variant (B.1.351) with the AS03 adjuvant system. The study found that the vaccine demonstrated robust immunogenicity and acceptable safety in both naïve and non-naïve individuals, with an overall vaccine effectiveness of 64.7% in preventing symptomatic COVID-19. The findings suggest that the bivalent vaccine could be a potential booster for individuals already exposed to the virus or vaccinated.

